Atea Pharmaceuticals, Inc.AVIRNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.23% | +1.23% | +1.48% | -0.60% | -6.36% |
| Weighted Average Shares Diluted Growth | +1.23% | +1.23% | +1.48% | -0.60% | -6.36% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -19.26% | -21.90% | -20.44% | -23.27% | -30.14% |
| Book Value per Share Growth | -22.13% | -21.91% | -19.69% | -23.06% | -26.45% |
| Debt Growth | -29.01% | -31.64% | -34.73% | -38.47% | -43.05% |
| R&D Expense Growth | -18.07% | -26.75% | -48.62% | -6.98% | +46.59% |
| SG&A Expenses Growth | -12.38% | +15.99% | -22.02% | -25.14% | -34.62% |